GlassScriptPhysician profile
Susan A Snider
NPI 1548652886
$2,233.55
in general payments reported to CMS, 2019-2025
29 companies · $598 in 2025
The $598 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $160 · 2022: $345 · 2023: $508 · 2024: $623 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,664 · Education: $65.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,663.86 |
| Education | $65.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $493.40 | 2023-2025 | Orgovyx, Gemtesa |
| Astellas Pharma US INC | $314.32 | 2021-2023 | Myrbetriq |
| 180 Medical, INC. | $249.10 | 2023-2025 | Cure Catheter, Bardia Urethral Catheter |
| Abbvie INC. | $196.89 | 2022-2025 | |
| Urogen Pharma, INC. | $100.14 | 2023-2025 | Jelmyto |
| Endo USA, INC. | $97.25 | 2025 | Aveed, Xiaflex |
| Myovant Sciences INC. | $77.87 | 2022 | |
| Endo Pharmaceuticals INC. | $76.04 | 2022-2024 | Aveed, Xiaflex |
| Accord Healthcare, INC. | $62.14 | 2023-2024 | |
| Progenics Pharmaceuticals, INC. | $51.08 | 2023-2024 | Pylarify |
| Procept Biorobotics Corporation | $49.09 | 2023-2025 | Aquabeam Robotic System |
| Rochester Medical Corporation | $48.71 | 2022 | |
| Janssen Biotech, INC. | $41.05 | 2025 | Erleada, Carvykti, Rybrevant |
| C. R. Bard, INC. & Subsidiaries | $39.46 | 2025 | Personal Catheter Intermittent Catheter |
| Antares Pharma, INC. | $38.82 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $38.13 | 2023-2024 | |
| Organogenesis INC. | $32.11 | 2024 | |
| Ambu INC. | $25.97 | 2024 | |
| Blue Earth Diagnostics | $23.02 | 2025 | Posluma |
| Immunitybio, INC. | $22.35 | 2025 | |
| Halozyme INC | $22.28 | 2023 | |
| Novartis Pharmaceuticals Corporation | $21.85 | 2025 | |
| Laborie Medical Technologies Corp. | $20.28 | 2025 | |
| Axonics, INC. | $20.28 | 2022 | |
| Tempus Ai, INC | $16.19 | 2024 | |
| Myriad Genetic Laboratories, INC. | $14.84 | 2024 | Prolaris |
| Sagent Pharmaceuticals | $14.06 | 2025 | Glydo |
| Abc Home Medical Supply, INC. | $13.80 | 2025 | |
| Koelis INC. | $13.03 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Snider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.